| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
60,190,000 |
| Market
Cap: |
270.25(M) |
| Last
Volume: |
1,702,056 |
Avg
Vol: |
1,697,350 |
| 52
Week Range: |
$3.39 - $9.95 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Anavex Life Sciences is a clinical stage biopharmaceutical company engaged in the development of therapeutics by applying medicine to central nervous system (CNS) diseases. Co.'s primary compound, ANAVEX®2-73, is being developed to treat Alzheimer's disease, Parkinson's disease and other CNS diseases, including rare diseases, such as Rett syndrome. Co.'s proprietary SIGMACEPTOR™ Discovery Platform produced small molecule drug candidates with certain modes of action, based on its understanding of sigma receptors. Compounds that have been subjects of Co.'s research include the following: ANAVEX®3-71, ANAVEX®1-41, ANAVEX®1066, and ANAVEX®1037.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
73,380 |
73,380 |
341,380 |
391,380 |
| Total Sell Value |
$374,972 |
$374,972 |
$2,514,282 |
$2,967,282 |
| Total People Sold |
1 |
1 |
1 |
2 |
| Total Sell Transactions |
1 |
1 |
2 |
3 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Skarpelos Athanasios |
10% Owner |
– – • |
2007-09-17 |
4 |
B |
$3.60 |
$333,000 |
D/D |
92,500 |
8,517,500 |
2.45 |
- |
|
| Skarpelos Athanasios |
10% Owner |
– – • |
2007-07-30 |
4 |
S |
$1.70 |
$1,615,000 |
D/D |
(950,000) |
8,425,000 |
|
- |
|
| Kalkanis George |
VP Strategic PlanningOfficer |
• – – |
2007-02-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
900,000 |
|
- |
|
| Skarpelos Athanasios |
10% Owner |
– – • |
2006-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
7,812,500 |
9,375,000 |
|
- |
|
| Lalach Harvey |
President & CEO |
• • – |
2006-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
500,000 |
600,000 |
|
- |
|
| Skarpelos Athanasios |
10% Owner |
– – • |
2006-04-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,562,500 |
|
- |
|
| Lalach Harvey |
PresidentOfficer |
• • – |
2006-04-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
100,000 |
|
- |
|
| Wu Yang |
President & CEO |
• • • |
2006-04-25 |
4 |
S |
$0.15 |
$121,875 |
D/D |
(812,500) |
0 |
|
- |
|
| Wu Pei Ru |
COO |
• • • |
2006-04-25 |
4 |
S |
$0.15 |
$127,500 |
D/D |
(850,000) |
0 |
|
- |
|
| Wu Yang |
officerTitle |
• • • |
2005-11-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
812,500 |
|
- |
|
| Wu Pei Ru |
officerTitle |
• • • |
2005-11-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
850,000 |
|
- |
|
86 Records found
|
|
Page 4 of 4 |
|
|
0.18 (4.18%) 
